EA201790017A1 - NEW MINERAL COMPOSITION - Google Patents

NEW MINERAL COMPOSITION

Info

Publication number
EA201790017A1
EA201790017A1 EA201790017A EA201790017A EA201790017A1 EA 201790017 A1 EA201790017 A1 EA 201790017A1 EA 201790017 A EA201790017 A EA 201790017A EA 201790017 A EA201790017 A EA 201790017A EA 201790017 A1 EA201790017 A1 EA 201790017A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mineral composition
new mineral
relates
present
therapy
Prior art date
Application number
EA201790017A
Other languages
Russian (ru)
Inventor
Эдуард Антониус Йоаннес Арнольдуссен
Original Assignee
Дедраф Холдинг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дедраф Холдинг Б.В. filed Critical Дедраф Холдинг Б.В.
Publication of EA201790017A1 publication Critical patent/EA201790017A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Настоящее изобретение относится к области терапии и предотвращения ментальных расстройств, в частности лечению депрессии, эмоционального выгорания и когнитивных расстройств. Конкретнее, настоящее изобретение относится к новой минеральной композиции, содержащей глицинат магния, глицинат цинка и селенометионин, возможно, в сочетании с пиколинатом хрома, таурином и/или витамином В6, подходящей для указанной терапии.The present invention relates to the field of therapy and prevention of mental disorders, in particular the treatment of depression, emotional burnout and cognitive disorders. More specifically, the present invention relates to a novel mineral composition comprising magnesium glycinate, zinc glycinate and selenomethionine, possibly in combination with chromium picolinate, taurine and / or vitamin B6, suitable for the indicated therapy.

EA201790017A 2014-06-24 2015-06-24 NEW MINERAL COMPOSITION EA201790017A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2013055 2014-06-24
PCT/NL2015/050460 WO2015199537A1 (en) 2014-06-24 2015-06-24 New mineral composition

Publications (1)

Publication Number Publication Date
EA201790017A1 true EA201790017A1 (en) 2017-06-30

Family

ID=52014299

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790017A EA201790017A1 (en) 2014-06-24 2015-06-24 NEW MINERAL COMPOSITION

Country Status (3)

Country Link
EP (1) EP3160459A1 (en)
EA (1) EA201790017A1 (en)
WO (1) WO2015199537A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1025644B1 (en) * 2017-10-13 2019-05-15 Synapharm Industrial Synthesis COMPOUND FOR TREATING DISEASE OR DISORDER OF THE CENTRAL NERVOUS SYSTEM IN A SUBJECT WHILE STIMULATING AND / OR RESTAURING NEURONAL PLASTICITY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206895A1 (en) * 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
ATE323479T1 (en) * 2000-06-16 2006-05-15 Matthias Dr Med Rath COMPOSITION FOR THE PREVENTION OF SMOOTH MUSCLE DISEASES CONTAINING ASCORBATE, ARGININE AND MAGNESIUM
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US7034012B2 (en) * 2002-11-01 2006-04-25 Matthias Rath Composition and method for prevention and treatment of arrhythmias
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
JP5744063B2 (en) * 2010-01-26 2015-07-01 リッジ ダイアグノスティックス，インコーポレイテッド Multiple biomarker panels for stratifying the disease severity of depression and monitoring treatment
NL2010214C2 (en) * 2013-01-31 2014-08-04 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.

Also Published As

Publication number Publication date
EP3160459A1 (en) 2017-05-03
WO2015199537A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
EA201790737A1 (en) COMBINED THERAPY
CR20140020A (en) METALOENZYM INHIBITING COMPOUNDS
EA201790575A1 (en) TRIAZOLOPIRASINONS AS PDE1 INHIBITORS
CU20140082A7 (en) PYRIMIDINES AND FUSIONATED TRIAZINS REPLACED AND THEIR USE
MX2018008105A (en) Metalloenzyme inhibitor compounds.
IN2014DN00286A (en)
IN2014MN00093A (en)
IN2014DN06792A (en)
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
EA201692109A1 (en) OPTIONS OF ANTIBODIES TO FACTOR D AND THEIR APPLICATION
IN2014MN01378A (en)
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201591278A1 (en) COMPOSITIONS CONTAINING C1-INH, AND METHODS OF PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH THE DEFICIENCY C1 inhibitor
EA201792157A1 (en) IMIDAZOPIRASINONS AS PDE1 INHIBITORS
EA201691314A1 (en) THERAPEUTIC WAYS AND COMPOSITIONS
EA201790312A1 (en) COMBINATION OF MEDICINES FOR THE TREATMENT OF MULTIPLE MYELOMA
MX2015014713A (en) Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer.
CY1117620T1 (en) THIRD CALCINE FOR USE IN TREATMENT OF Cystic Fibrosis
MX2015011518A (en) Met-binding agents and uses thereof.
UY34575A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND / OR OBESITY
EA201691108A1 (en) Quinazoline-THF-Amines as PDE1 Inhibitors
TW201613628A (en) Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders
MX2016003293A (en) Methods and compositions for treatment of chlamydial infection and related diseases and disorders.
EA201791819A1 (en) COMBINED THERAPY WITH ANTIBODY CONJUGATE AGAINST CD19 WITH MEDICINE AND VINCRISTINE
MX370436B (en) Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients which have been subjected to gastric bypass-surgery.